Apodex Launches Free AI Services for Drug Research

REDWOOD CITY, Calif., Oct. 8, 2026 /CourierPR/ -- Apodex, a company specializing in AI-driven drug research, has launched a free service aimed at supporting small and mid-sized pharmaceutical and biotech companies. The initiative seeks to democratize access to advanced AI technologies, which have the potential to significantly accelerate drug development processes.

Founded by Tianqiao Chen, Apodex offers a range of services designed to assist in the research and development of new treatments. These services include the Clinical Trial Forecasting Lab, which predicts the probability of success for ongoing clinical trials and provides detailed explanations for its forecasts. More than 600 such forecasts are currently available, with each one being verified against the actual trial outcomes.

The company’s flagship service, the Clinical Trial Forecasting Lab, is just one component of Apodex’s comprehensive research infrastructure. This infrastructure includes tools for drug repurposing and reformulation, drug-drug interaction analysis, and drug safety assessment. According to Dr. Heng Ji, Head of the Drug Research Computing Center at Apodex, the system integrates a large-scale biomedical knowledge network, specialized computational tools, and agentic workflows to support drug development.

The services are currently available free of charge at drug.apodexlab.ai. Companies interested in utilizing Apodex’s services can visit the website to begin their research. Terms will be agreed upon before any work begins, ensuring a tailored approach to each company’s specific needs.

By providing these services, Apodex aims to bridge the gap between large pharmaceutical companies and smaller entities, enabling a broader range of organizations to benefit from cutting-edge AI technologies in drug research.